Concepedia

Author

Thomas Gauler

University of Duisburg-Essen

Also Known As

R. Görges, T C Gauler, T Gauler, T. C. Gauler, T. Gauler, T.C. Gauler, Thomas C Gauler, Thomas C. Gauler, Thomas Christoph Gauler, Thomas Gauler

269

Publications

12.4K

Citations

43

H-Index

81

Concepts

All Affiliations

University of Duisburg-EssenEssen University HospitalRuhrlandklinikCharité - Universitätsmedizin BerlinDeutschen Konsortium für Translationale Krebsforschung
TG

About

Thomas Gauler is an author at University of Duisburg-Essen specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

47

2.4K

2

Health Sciences

13

15

790

3

Engineering

2

2

76

4

Public Health

1

1

150

5

Biostatistics

1

1

27

Thomas Gauler

×

85

Publications

10.7K

Citations

38

H-Index

YearCitations

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George,

New England Journal of Medicine

2015

5.8K

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette,

The Lancet Oncology

2015

386

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

Wilfried Eberhardt, Christoph Pöttgen, Thomas Gauler,

Journal of Clinical Oncology

2015

353

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George,

Cancer

2020

327

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

S. Krege, J. Beyer, Rainer Souchon,

European Urology

2008

252

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Bernard Escudier, Padmanee Sharma, David F. McDermott,

European Urology

2017

247

Value of 18F-Fluoro-2-Deoxy-<scp>d</scp>-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy

Christoph Pöttgen, S. Levegrün, Dirk Theegarten,

Clinical Cancer Research

2006

205

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

G. Goeckenjan, H. Sitter, Michael Thomas,

Pneumologie

2010

150

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104)

Volker Heinemann, Ursula Vehling‐Kaiser, Dirk Waldschmidt,

Gut

2012

120

Thoracic Staging in Lung Cancer: Prospective Comparison of <sup>18</sup>F-FDG PET/MR Imaging and <sup>18</sup>F-FDG PET/CT

Philipp Heusch, Christian Buchbender, Jens Köhler,

Journal of Nuclear Medicine

2014

118

Page 1